Company Overview and News
American Express Company (AXP - Free Report) reported first-quarter 2018 adjusted earnings per share (EPS) of $1.86, beating the Zacks Consensus Estimate by 8.77%. Moreover, the bottom line witnessed a marked 38% year-over-year improvement.
Synchrony Financial (SYF - Free Report) will release first-quarter 2018 results on Apr 20, 2018, before the market opens. Last quarter, the company delivered a positive earnings surprise of 11.11%.
American Express Company (AXP - Free Report) is expected to report first-quarter results on Apr 18. The performance is likely to reflect gains from its four strategic focus areas — strengthening leadership in the premium consumer segment; extending leadership in commercial payments and in particular with small and medium-sized enterprises; enhancing its digital platform; and strengthening its global integrated network to provide unique value.
Walmart Inc.’s (WMT - Free Report) latest contract with Postmates is likely to intensify the online grocery delivery competition among retailers — which was largely triggered by Amazon’s (AMZN - Free Report) takeover of Whole Foods Market last year. Ever since the e-commerce biggie’s intrusion into the grocery space, retailers, particularly Walmart, have been making constant attempts to stay firm in the game.
Ant Financial is hoping to raise at least US$10 billion in a funding round that could make the Chinese payments giant controlled by Alibaba Group the world’s biggest start-up, according to sources familiar with the matter.
A logo of Ant Financial is displayed at the Ant Financial event in Hong Kong, China November 1, 2016. — Reuters picSINGAPORE, April 11 — China’s Ant Financial is seeking to raise at least US$10 billion (RM38.6 billion) in a funding round that could make the payments giant controlled by Alibaba-founder Jack Ma the most valuable startup in the world, according to people familiar with the matter.
Appetite among US investors has been strong this year for tech sector debuts by Dropbox, Spotify and Zscaler, easing concerns raised by the fall in Snap Inc’s shares last year.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
(Reuters) - China’s Ant Financial Services Group is in talks with investors to raise at least $8 billion in its next planned round of funding, potentially valuing the company at about $150 billion ahead of an expected stock market floatation, people with knowledge of the plan said.
Alibaba (BABA) stock fell 8.7% last week, which ended April 6, 2018, to close at $169.87. The stock has generated returns of 55% in the last 12 months and -10.6% in the last month after rising almost 97% in 2017. The stock is now trading 56% above its 52-week low of $108.84 and 18% below its 52-week high of $206.20.
Bengaluru: Chinese billionaire Jack Ma’s online payments business Ant Financial now plans to raise $9 billion in its next planned round of funding, potentially valuing the company at $150 billion ahead of an expected stock market flotation, the Wall Street Journal reported on Tuesday.
Hong Kong: Ant Financial is in talks to raise at least $10 billion in a funding round that could value the Chinese internet giant controlled by Alibaba-founder Jack Ma at $150 billion, according to people familiar with the matter.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET